

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Rina Aharoni et al.
U.S. Serial No. : Not Yet Known (Continuation
Application of PCT/US99/16747, filed
July 23, 1999)
Filed : Herewith
For : TREATMENT OF AUTOIMMUNE CONDITIONS
WITH COPOLYMER 1 AND RELATED
COPOLYMERS AND PEPTIDES

1185 Avenue of the Americas
New York, New York 10036
January 23, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

In the Declaration and Power of Attorney

On page 2, please delete the claim to benefit of U.S. Provisional
Application No. 60/123,675, filed March 9, 1999.

In the Specification

Please replace pages 1-76 with substitute pages 1-58 attached
hereto as **Exhibit 1**. The amendments to the specification are
indicated by underline of added material and strikeout of deleted
material in the pages attached hereto as **Exhibit 2**.

In the Claims

Please cancel claims 59-91, 121-127 and 137-156 and amend claim
15 as set forth in the replacement set of claims attached hereto
as **Exhibit 3**. The amendments to the previously pending claims
are indicated by underline of added material and strikeout of
deleted material set forth in attached **Exhibit 4**.

Applicants: Yaacov Herzig et al.
Serial No.: 09/260,755
Filed : March 2, 1999
Page 2

In addition, solely for the purpose of reducing the filing fee, please cancel claims 46-58, 92-120, 128-133 and 135-136 as set forth in the replacement set of claims attached hereto as **Exhibit 3**. The claims canceled solely to reduce filing fees are indicated by gray high-lighting as set forth in attached **Exhibit 4**.

In the Abstract

Please replace the abstract with the new abstract attached hereto as **Exhibit 5**. The amendments to the abstract are indicated by underline of added material and strikeout of deleted material in attached **Exhibit 6**.

REMARKS

Claims 1-156 were pending in this application. By this Amendment, applicants have canceled claims 59-91, 121-127 and 137-156 without prejudice to pursue the subject matter of these claims in this or a subsequent application. Applicants have also amended claim 15. Thus, claims 1-58, 92-120 and 128-136 are now pending in the subject application.

Support for the amendment to page 6, line 4 and claim 15 may be found, *inter alia*, on page 5, line 30 to page 6, line 5. It would be evident to one skilled in the art that the molar ratios of a "terpolymer consisting essentially of tyrosine, glutamic acid and alanine" would pertain to the recited amino acids, i.e., tyrosine, glutamic acid and alanine. Thus, for this terpolymer, applicants have replaced "the molar ratio of from about 0.005 to about 0.25 tyrosine, from about 0.005 to about 0.3 glutamic acid, and from about 0.005 to about 0.8 lysine" with --the molar ratio of from about 0.005 to about 0.25 tyrosine, from about 0.005 to about 0.3 glutamic acid, and from about 0.005 to about 0.8

Applicants : Rina Aharoni et al.
U.S. Serial No. : Not Yet Known (Continuation
Application of PCT/US99/16747, filed
July 23, 1999)
Filed : Herewith
Page 3

alanine--

The replacement of "Aa amino acid" with --An amino acid-- on page 11, line 13 is made to correct a typographical error.

On page 11, line 18, another typographical error is corrected by the substitution of "polypeptide" for --polypepide--.

Yet another typographical error appears on page 13, line 10, which applicants have corrected by replacing "consistently essentially of" with --consisting essentially of--.

Support for the amendments to page 26, line 18, page 27, lines 4 and 27, page 28, lines 12 and 14, page 29, lines 5, 21 and 23 and page 30, line 15 may be found, *inter alia*, on page 30, line 30.

Support for the amendment to page 45, footnote 2 (line 26) may be found, *inter alia*, on page 43, line 22.

Support for the amendment to page 47, line 12 may be found, *inter alia*, on page 47, line 12.


The amendment to page 56, line 10 is made to correct a typographical error. It would be obvious to one skilled in the art that a concentration of "I mM" should have been written as --1 mM--.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants : Rina Aharoni et al.
U.S. Serial No. : Not Yet Known (Continuation
Application of PCT/US99/16747, filed
July 23, 1999)
Filed : Herewith
Page 4

No fee is deemed necessary in connection with the filing of this
Amendment. However, if any additional fee is deemed necessary,
authorization is hereby given to charge the amount of any such
fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

2025-07-23 14:00:00